Key Takeaways:
- FDA identifies cases of liver injury in patients taking an Amgen drug.
- Agency urges immediate discontinuation if liver damage is suspected.
- Warning increases regulatory risk and could impact the drug's sales.
Back
Back
FDA Warns of Liver Injury Risk With Amgen's Autoimmune Drug
The U.S. Food and Drug Administration on Monday warned of potential liver injury in patients using an Amgen Inc. drug for rare autoimmune diseases.
The agency urged healthcare providers in a statement to closely monitor patients and discontinue the treatment promptly if liver damage is suspected.
The warning, announced on March 30, 2026, follows the identification of several cases of clinically significant liver injury in patients using the treatment.
The safety alert could lead to a drop in Amgen's stock price and may trigger a reassessment of the drug's market potential.
The FDA's warning introduces significant uncertainty for the drug's future revenue and raises the possibility of litigation. Investors will be closely watching for any updates from Amgen regarding the issue and the company's next earnings report for any commentary on the financial impact.
This article is for informational purposes only and does not constitute investment advice.
Features
Resources
© 2026 Finture Development Limited. All rights reserved